Werner Gladdines retweeted
๐งญ Board update at Immunic: Michael W. Bonney has been appointed new Chair of our Board of Directors.
๐ง With more than three decades of experience in the biopharmaceutical industry, including deep expertise in #MultipleSclerosis (#MS) and central nervous system (#CNS) markets, Mike brings valuable perspectives as we advance our clinical programs and prepare for upcoming milestones. His background spans senior leadership roles at Biogen, including for the launch and commercial success of MS drug Avonexยฎ, as well as CEO of Cubist Pharmaceuticals and roles of increasing responsibility at Zeneca Pharmaceuticals.
His strong experience further strengthens our Board as we continue to advance our phase 3 #ENSURE trials in relapsing multiple sclerosis (#RMS) and plan to initiate a confirmatory phase 3 program in primary progressive multiple sclerosis (#PPMS).
We also thank Simona Skerjanec for her dedicated leadership as Interim Chairperson and her continued role on our Board. ๐
Get all the details here: bit.ly/4uWM1wW
$IMUX
Werner Gladdines retweeted
๐ข Patent Update
๐ก๏ธ The European Patent Office, @EPOorg, has granted a key European patent covering label-relevant dosing regimens for #Immunicโs lead candidate, our #Nurr1 activator and #DHODH inhibitor, across all indications, including #MultipleSclerosis (#MS). ๐ช๐บ
๐ The patent broadly protects #vidofludimus and its salt, solvate and free acid forms used according to the label-mandated dosing scheme. It is expected to provide protection in Europe into 2038 and may be eligible for a Supplementary Protection Certificate (SPC), potentially extending market exclusivity into 2043.๐ง
๐งฉ The #patent was previously granted by the U.S. Patent and Trademark Office, @uspto, in 2023 and supports Immunicโs multi-layered #IntellectualProperty strategy for the drug with protection expected at least into 2041 in the United States and 2039 in Europe.
๐ Learn more here: bit.ly/46Tyqg9
#DrugDevelopment $IMUX #IMU838
Werner Gladdines retweeted
We are #hiring a working student in #communications!
Are you creative, communicative, and ready to dive into the world of #biotech? Join our #PR and #IR team in Grรคfelfing, just outside of Munich! โจ
Curious about public and investor relations at #Immunic, learn more here:
๐ imux.com/careers
$IMUX #nowhiring #jobopportunity #applynow
Werner Gladdines retweeted
๐ข #Immunic announces completion of enrollment for both phase 3 #ENSURE trials in relapsing #MultipleSclerosis (#RMS) and presents additional data underlining the positive outcome of the phase 2 CALLIPER trial in progressive mulitple sclerosis (PMS) โจ
๐ Get all the details here: bit.ly/4dOw840
#vidofludimus #IMU838 #neurology #neuroprotection #MS #PMS #MSResearch $IMUX
Werner Gladdines retweeted
๐ข #๐๐บ๐บ๐๐ป๐ถ๐ฐ ๐๐ป๐ป๐ผ๐๐ป๐ฐ๐ฒ๐ ๐ฃ๐ฟ๐ถ๐ฐ๐ถ๐ป๐ด ๐ผ๐ณ ๐ข๐๐ฒ๐ฟ๐๐๐ฏ๐๐ฐ๐ฟ๐ถ๐ฏ๐ฒ๐ฑ $๐ฒ๐ฑ ๐ ๐ถ๐น๐น๐ถ๐ผ๐ป ๐จ๐ป๐ฑ๐ฒ๐ฟ๐๐ฟ๐ถ๐๐๐ฒ๐ป ๐ฃ๐๐ฏ๐น๐ถ๐ฐ #๐ข๐ณ๐ณ๐ฒ๐ฟ๐ถ๐ป๐ด
๐ฐ Today, we announced the pricing of an underwritten #PublicOffering, securing approx. $65 million in initial gross proceeds, with the potential to receive up to an aggregate of $130 million of additional gross proceeds if all tranches are exercised in full for cash.
๐ The net proceeds will support the continued advancement of our clinical development pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, as well as general corporate purposes.
๐ Learn more here: bit.ly/3HtI2UU
$IMUX #immunology #biotechnology
Werner Gladdines retweeted
๐จ #๐๐บ๐บ๐๐ป๐ถ๐ฐ ๐๐ป๐ป๐ผ๐๐ป๐ฐ๐ฒ๐ ๐ฃ๐ผ๐๐ถ๐๐ถ๐๐ฒ ๐ฃ๐ต๐ฎ๐๐ฒ ๐ฎ #๐๐๐๐๐๐ฃ๐๐ฅ ๐ง๐ฟ๐ถ๐ฎ๐น ๐ฅ๐ฒ๐๐๐น๐๐! ๐จ
Key highlights:
๐น 20% reduction in relative risk of 24-week confirmed disability worsening (24wCDW) events in overall #PMS study population compared to placebo
๐น 30% reduction in relative risk of 24wCDW events compared to placebo in high unmet need population of #PPMS
๐น Consistent reduction of disability worsening in subpopulations without inflammatory lesions at baseline
๐น 29% reduction in relative risk of 24wCDW events in patients without gadolinium-enhancing lesions at baseline compared to placebo
๐น 20% reduction in annualized rate of thalamic brain volume loss compared to placebo
๐น Confirmed favorable safety and tolerability profile observed in previous clinical trials; no new safety signals identified
๐ Join our webcast today at 8am ET: bit.ly/4iDSTZs
All details: โถ๏ธ bit.ly/42XimHr
#vidofludimus #IMU838 #MultipleSclerosis #MS #neurology $IMUX
Werner Gladdines retweeted
๐ง How is #Immunic advancing potential new #MS treatment options? Our phase 3 #ENSURE trials can continue as planned, according to a recent positive interim analysis.
Learn more details in @BioWorldโs latest article: โก๏ธ bit.ly/3NHoTid
#MultipleScerlosis #PMS #RMS #Vidofludimus $IMUX #Immunic
Werner Gladdines retweeted
๐ข$IMUX announced a ๐ฝ๐ผ๐๐ถ๐๐ถ๐๐ฒ outcome of the phase 3 #ENSURE interim analysis of #vidofludimus calcium in #RMS! An unblinded IDMC confirmed futility criteria were not met & recommended continuing the trial without changes.
Learn more details here: โถ bit.ly/4dUGzld or join #Immunic's webcast today 8am ET: โถ bit.ly/48n36Gg
#ClinicalTrials #IMU838 #MS #MultipleSclerosis #Neuroprotection #Nurr1 #DHODH
Werner Gladdines retweeted
๐ As #ECTRIMS2024 comes to a close, the $IMUX team is grateful to everyone who made it so valuable! ๐ค Thank you to all who stopped by to meet with us. Together, we are moving forward to find new treatments for progressive and relapsing #MultipleSclerosis.
@ECTRIMS #MS #Immunic
I am honored and excited about my new role as Chief Development Officer at @ImmunicInc. The Nasdaq tower display is a proud moment, and I am grateful for the team's support and hard work that made this possible. A big thank you to @JessyBrett and the @Nasdaq team for the gesture
๐ Congratulations, once again, on your #promotion to Chief Development Officer, Werner! Your hard work and dedication have truly paid off. This display at the #Nasdaq tower is well-deserved. Here's to many more successes and milestones ahead! ๐
$IMUX #Immunic @NasdaqExchange
1
3
141
Werner Gladdines retweeted
๐ Congratulations, once again, on your #promotion to Chief Development Officer, Werner! Your hard work and dedication have truly paid off. This display at the #Nasdaq tower is well-deserved. Here's to many more successes and milestones ahead! ๐
$IMUX #Immunic @NasdaqExchange
Werner Gladdines retweeted
Join us in welcoming @ImmunicInc to the Closing Bell. ๐๏ธ
$IMUX is developing a pipeline of next-generation selective oral therapies focused on offering patients with chronic inflammatory and autoimmune diseases new and clinically meaningful treatment options. #NasdaqListed
nasdaq.com/events/immunic-inโฆ
Immunic rings the closing bell
18
Werner Gladdines retweeted
Thank you, @TheStevieAwards for rewarding us with 3 Gold & 1 Bronze Stevie Awards for our #MS R&D Webcast & website design.
Now, we want to challenge our team even further & secure the prize for the most creative winning photo. Please like, retweet & support!
#StevieWinner2023
Werner Gladdines retweeted
Today, 9:30am-4:00pm CT, at @DDWMeeting, Dr. Franziska Buriรกnek, Senior Medical Director at $IMUX, presents an e-poster, entiteled: "First-in-Human Trial of #IMU856, an Orally Available Regulator Of Barrier Function For The Treatment Of #CeliacDisease".
#DDW #DDW2023 #Immunic
Werner Gladdines retweeted
โผ๏ธNEWSโผ๏ธ
During @DDWMeeting, today, we present clinical and preclinical data of #IMU856, including its #ModeOfAction as a potent small molecule modulator of #SIRT6.
Learn more: https://teapawt.net/t.co/4mDUIzGk5e
#DigestiveDiseaseWeek #DDW #DDW2023 #Immunic $IMUX
Werner Gladdines retweeted
โถ๏ธMay 3-4: Meet $IMUX's VP, Clinical Development Operations, Werner Gladdines at the "Outsourcing in Clinical Trials (OCT) Europe".
Let's learn about #FutureTrends and get the latest knowledge about disruptors in the #ClinicalTrials space.
@Arena_Pharma #OCTEurope2023
Exciting times at Immunic. The clinical development operations group is further expanding its capabilities with 2 new exciting roles in the area of clinical compliance and vendor management. These roles have direct impact on the future of our three oral sโฆlnkd.in/ewFU48FZ
26
Werner Gladdines retweeted
Today is #WorldIBDDay2022!
$IMUX is developing a potential therapy to alleviate the suffering of people with #UlcerativeColitis. #VidofludimusCalcium is in a phase 2 clinical trial in moderate-to-severe #UC, for which top-line data is expected in June.
#IBDhasNoAge #GameOverIBD
Werner Gladdines retweeted
$IMUX to participate in upcoming conferences: https://teapawt.net/t.co/Ee1RuzVvfP
@BRileyFinancial Neuro & Ophthalmology Conference (Apr 27-28); @ArenaIntOCT Outsourcing in Clinical Trials Europe (May 4-5); @BioCentury #BioEquity Europe (May 16-18; 23-24); @DDWMeeting #DDW2022 (May 21-24)

























